The first human trial of a treatment using induced pluripotent stem cells has received conditional approval from an institutional review board in Japan.
Daily News Roundup
The first human trial of a treatment using induced pluripotent stem cells has received conditional approval from an institutional review board in Japan.
Under new plans to reduce the European Union’s overall spending, science funding did relatively well, but research leaders want more—and they may well get it.
A new study disputes findings of a 2011 analysis suggesting that black researchers are funded less than their equally qualified white peers.
Researchers uncover more evidence that reprogrammed stem cells are not attacked by the immune system, suggesting they may one day serve as effective therapies.
After a year-long voluntary moratorium to discuss regulations and safety measures, scientists are set to resume controversial H5N1 research.
Long-term, life, and disability insurers may still be able to deny coverage to patients with a genetic disease, under current nondiscrimination legislation.
The US Food and Drug Administration approves the first flu vaccine made from recombinant proteins rather than a weakened virus.
Fecal transplants outcompeted traditional antibiotics at curing a deadly intestinal infection.
Transplanting synthetic stool made of beneficial microbes cures deadly diarrheal infections in two patients.
The Cancer Prevention and Research Institute of Texas has agreed to stop awarding new grants until it addresses concerns about the integrity of is review process.